Merck Presents P-III Trial (KEYNOTE-966) Results of Keytruda for Advanced or Unresectable Biliary Tract Cancer at AACR 2023 Published in The Lancet
Shots:
- The P-III trial evaluating Keytruda (200mg, q3w for ~2yrs.) + gemcitabine & cisplatin vs PBO + gemcitabine & cisplatin in 1069 patients
- The results showed an improvement in OS, a 17% reduction in risk of death after a median follow-up of 25.6mos., m-OS was 12.7mos. vs 10.9mos., 1 & 2 yr. OS rate was 52% & 24.9% vs 44% vs 18.1%, respectively. The OS results were consistent across subgroups & the results are being shared with regulatory authorities globally
- The safety profile was consistent with prior reported studies, grade 3-4 TRAEs (70% vs 69%); TRAEs led to death (2% vs 1%) with no new safety signals, grade 3-4 immune-mediated AEs (7% vs 4%); patient experienced immune-mediated AEs that resulted in death (1%)
Ref: BusinessWire | Image: Merck
Related News:- Merck and Eisai Highlighted Update on P-III Trials (LEAP-003) and (LEAP-017) of Keytruda (pembrolizumab) + Lenvima (lenvatinib)
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
